You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

CLINICAL TRIALS PROFILE FOR VISIPAQUE 270


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Visipaque 270

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT00209404 ↗ Iodixanol in Multidetector-Row Computed Tomography-Coronary Angiography (MDCT-CA) Completed GE Healthcare Phase 4 2005-07-01 Image quality in coronary artery computed tomography is influenced by the heart rate variation during the examination. The purpose of this clinical trial is to investigate the change in heart rate following injection of a contrast medium called Visipaque™ (iodixanol). Image quality and diagnostic quality of the examination will be evaluated.
NCT00209417 ↗ Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography Terminated ABX CRO Phase 4 2005-06-01 It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and diabetes mellitus may be at increased risk. It is widely accepted to use low-osmolar or iso-osmolar contrast media, especially in patients at risk for contrast media-induced nephropathy. However, little is known about the intravenous use of X-ray contrast media in risk patients, such as contrast-enhanced CT examinations. The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the injection of contrast media. Due to the iso-osmolar feature, it is expected less influence on renal function following administration of iodixanol. A standard hydration procedure, based on available guidelines will be given to all patients to prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured before and up to 7 days after contrast media administration to evaluate the effects on renal function.
NCT00209417 ↗ Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography Terminated ABX-CRO Phase 4 2005-06-01 It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and diabetes mellitus may be at increased risk. It is widely accepted to use low-osmolar or iso-osmolar contrast media, especially in patients at risk for contrast media-induced nephropathy. However, little is known about the intravenous use of X-ray contrast media in risk patients, such as contrast-enhanced CT examinations. The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the injection of contrast media. Due to the iso-osmolar feature, it is expected less influence on renal function following administration of iodixanol. A standard hydration procedure, based on available guidelines will be given to all patients to prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured before and up to 7 days after contrast media administration to evaluate the effects on renal function.
NCT00209417 ↗ Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography Terminated Averion International Corporation Phase 4 2005-06-01 It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and diabetes mellitus may be at increased risk. It is widely accepted to use low-osmolar or iso-osmolar contrast media, especially in patients at risk for contrast media-induced nephropathy. However, little is known about the intravenous use of X-ray contrast media in risk patients, such as contrast-enhanced CT examinations. The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the injection of contrast media. Due to the iso-osmolar feature, it is expected less influence on renal function following administration of iodixanol. A standard hydration procedure, based on available guidelines will be given to all patients to prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured before and up to 7 days after contrast media administration to evaluate the effects on renal function.
NCT00209417 ↗ Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography Terminated Covance Phase 4 2005-06-01 It is well known that X-ray contrast media can affect kidney function in some patients, especially when administered intra-arterially, and patients who already suffer from reduced kidney function and diabetes mellitus may be at increased risk. It is widely accepted to use low-osmolar or iso-osmolar contrast media, especially in patients at risk for contrast media-induced nephropathy. However, little is known about the intravenous use of X-ray contrast media in risk patients, such as contrast-enhanced CT examinations. The main purpose of this study is to evaluate and compare the effects on kidney function of two contrast media, the iso-osmolar iodixanol and the low-osmolar iopamidol in patients at risk of kidney damage associated with the injection of contrast media. Due to the iso-osmolar feature, it is expected less influence on renal function following administration of iodixanol. A standard hydration procedure, based on available guidelines will be given to all patients to prevent negative effects on the kidneys. Serum creatinine (SCr ) concentrations will be measured before and up to 7 days after contrast media administration to evaluate the effects on renal function.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 5 of 5 entries

Clinical Trial Conditions for Visipaque 270

Condition Name

52220-0.500.511.522.533.544.555.5Coronary Artery DiseaseDiabetes MellitusCardio-Renal SyndromePeripheral Arterial Occlusive Disease[disabled in preview]
Condition Name for Visipaque 270
Intervention Trials
Coronary Artery Disease 5
Diabetes Mellitus 2
Cardio-Renal Syndrome 2
Peripheral Arterial Occlusive Disease 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

655400123456Renal InsufficiencyKidney DiseasesCoronary Artery DiseaseMyocardial Ischemia[disabled in preview]
Condition MeSH for Visipaque 270
Intervention Trials
Renal Insufficiency 6
Kidney Diseases 5
Coronary Artery Disease 5
Myocardial Ischemia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Visipaque 270

Trials by Country

+
Trials by Country for Visipaque 270
Location Trials
United States 43
China 12
United Kingdom 3
France 2
Korea, Republic of 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for Visipaque 270
Location Trials
New Jersey 12
California 3
New York 3
Alabama 3
Minnesota 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Visipaque 270

Clinical Trial Phase

70.0%6.7%20.0%00246810121416182022Phase 4Phase 3Phase 1/Phase 2[disabled in preview]
Clinical Trial Phase for Visipaque 270
Clinical Trial Phase Trials
Phase 4 21
Phase 3 2
Phase 1/Phase 2 1
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

56.7%26.7%10.0%6.7%024681012141618CompletedTerminatedNot yet recruiting[disabled in preview]
Clinical Trial Status for Visipaque 270
Clinical Trial Phase Trials
Completed 17
Terminated 8
Not yet recruiting 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Visipaque 270

Sponsor Name

trials0123456789GE HealthcareBracco Diagnostics, IncGuerbet[disabled in preview]
Sponsor Name for Visipaque 270
Sponsor Trials
GE Healthcare 9
Bracco Diagnostics, Inc 8
Guerbet 4
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

55.4%42.9%0051015202530IndustryOtherU.S. Fed[disabled in preview]
Sponsor Type for Visipaque 270
Sponsor Trials
Industry 31
Other 24
U.S. Fed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Visipaque 270: A Comprehensive Overview of Clinical Trials, Market Analysis, and Projections

Introduction

Visipaque 270, also known as iodixanol, is a radiographic contrast medium widely used in various medical imaging procedures. This article delves into the clinical trials, market analysis, and future projections for Visipaque 270, providing a thorough understanding of its role and potential in the medical industry.

Clinical Trials and Efficacy

Patient Comfort and Safety

Clinical trials have consistently shown that Visipaque 270 offers superior patient comfort compared to other contrast media. Studies involving 1950 patients across 18 European clinical vascular trials indicated that iodixanol resulted in less pain and heat sensation after vascular injections[1].

Renal Safety

Extensive studies have demonstrated the renal safety of Visipaque 270. The drug showed minimal changes in glomerular filtration rate and serum creatinine levels, similar to other nonionic contrast media. Additionally, the excretion of marker enzymes for renal tubular cell function was generally lowest for Visipaque, indicating its high tolerability in the kidneys[1].

Cardiac Safety

Electrophysiological and hemodynamic studies revealed that Visipaque 270 had minimal or no adverse effects on cardiac function, making it a safer option for patients with cardiovascular conditions[1].

Adverse Events

In controlled clinical trials involving 1244 adult patients, Visipaque 270 reported adverse events in 19.9% of patients, which is comparable to or slightly lower than other iodinated contrast agents. Common adverse events included chest pain, nausea, and diarrhea, with a higher incidence in women than men[2][3].

Market Analysis

Indications and Usage

Visipaque 270 is indicated for various medical imaging procedures, including intra-arterial digital subtraction angiography, angiocardiography, CT imaging of the head and body, excretory urography, and peripheral venography. Its versatility and safety profile make it a preferred choice among healthcare professionals[4].

Market Demand

The demand for radiographic contrast media is driven by the increasing need for diagnostic imaging in healthcare. With an aging population and rising incidence of chronic diseases, the market for contrast agents like Visipaque 270 is expected to grow.

Pricing and Availability

The cost of Visipaque 270 varies depending on the concentration and volume. For example, a 500 milliliter supply of the 270 mg/mL solution can range from $521.82 to $567.42 for the 320 mg/mL solution. This pricing makes it competitive in the market, although costs can fluctuate due to supply chain factors[5].

Market Projections

Growth Drivers

The market for Visipaque 270 is expected to grow due to several factors:

  • Increasing Diagnostic Imaging Procedures: The rise in chronic diseases and the need for accurate diagnoses will drive the demand for contrast agents.
  • Technological Advancements: Improvements in imaging technologies will enhance the utility and safety of contrast media like Visipaque 270.
  • Expanding Healthcare Infrastructure: Growing healthcare infrastructure in developing countries will increase the demand for diagnostic imaging and, consequently, for contrast agents[4].

Market Challenges

Despite the positive outlook, there are challenges to consider:

  • Competition: The market for radiographic contrast media is competitive, with several other agents available.
  • Regulatory Scrutiny: Strict regulatory requirements and safety monitoring can impact market dynamics.
  • Economic Factors: Fluctuations in pricing and availability due to supply chain issues can affect market stability[5].

Key Takeaways

  • Clinical Efficacy: Visipaque 270 has demonstrated superior patient comfort and safety in clinical trials.
  • Market Demand: The demand for Visipaque 270 is driven by the increasing need for diagnostic imaging.
  • Pricing and Availability: The drug is competitively priced, but costs can vary due to supply chain factors.
  • Market Projections: The market for Visipaque 270 is expected to grow due to increasing diagnostic imaging procedures and technological advancements.

FAQs

What are the common indications for Visipaque 270?

Visipaque 270 is indicated for intra-arterial digital subtraction angiography, angiocardiography, CT imaging of the head and body, excretory urography, and peripheral venography[4].

What are the common adverse events associated with Visipaque 270?

Common adverse events include chest pain, nausea, diarrhea, and edema. Women tend to report adverse events more frequently than men[2][3].

How does Visipaque 270 compare to other contrast media in terms of patient comfort?

Visipaque 270 offers better patient comfort, with less pain and heat sensation after vascular injections compared to other contrast media[1].

What are the key factors driving the market growth for Visipaque 270?

The market growth is driven by the increasing need for diagnostic imaging, technological advancements, and expanding healthcare infrastructure[4].

Are there any specific precautions or contraindications for Visipaque 270?

Yes, Visipaque 270 is contraindicated for intrathecal use and should be used with caution in patients with severe renal impairment, cardiovascular disease, and other specific conditions[4].

Sources

  1. PubMed: Results of the first comparative clinical studies on Visipaque.
  2. RxList: Visipaque (Iodixanol Injectable Contrast Medium).
  3. GE Healthcare: VISIPAQUE PBP-USPi-022022 Final.pdf.
  4. eMPR: VISIPAQUE 270 Prescription & Dosage Information.
  5. Drugs.com: Visipaque Prices, Coupons, Copay Cards & Patient Assistance.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.